header-2.jpg
Grants

Discovery of new therapeutic targets for aggressive prostate cancer

This project aims to discover new therapeutic targets for a particularly aggressive and therapy resistant form of prostate cancer known as Neuroendocrine prostate cancer (NEPC). Current clinical therapies are not effective at inhibiting the growth and spread of NEPC and men diagnosed with NEPC have a very poor prognosis. It is hoped that findings from our study will reveal new therapeutic strategies to specifically kill this form of prostate cancer and improve outcomes for men with NEPC.

Investigators

Brett Hollier APCRC-Q, IHBI, QUT, TRI
Brian Gabrielli Mater Research Institute, UQ, TRI
Ian Vela APCRC-Q, IHBI, QUT, TRI, PAH

Duration

2018 - 2018

Funding

 

Prostate Cancer Foundation of Australia $100 000